Format

Send to

Choose Destination
Mol Cancer Ther. 2010 Jun;9(6):1485-8. doi: 10.1158/1535-7163.MCT-10-0156. Epub 2010 May 25.

Successful treatment of Castleman's disease with interleukin-1 receptor antagonist (Anakinra).

Author information

1
Department of Investigational Cancer Therapeutics, (Phase I Clinical Trials Program), The University of Texas, M.D. Anderson Cancer Center, Houston, Texas 77030, USA.

Abstract

Castleman's disease (CD) is a very rare lymphoproliferative disorder whose underlying pathophysiology is not fully understood and for which no standard treatment exists. Because interleukin-1 (IL-1) might promote the production of interleukin-6 (IL-6), a key pathogenic factor for the disease, we hypothesized that blocking the interleukin-1 receptor would be a useful therapy for CD. We report the case of a 61-year-old woman with CD who had undergone multiple treatments, including cladribine, rituximab, steroids, etanercept, and anti-IL-6 monoclonal antibody, and whose disease was refractory to all of these treatments. She was started on the recombinant IL-1 receptor antagonist, Anakinra, at a subcutaneous dose of 100 mg daily. Within one week, her fatigue and anorexia markedly improved, and her laboratory abnormalities, including anemia, thrombocytosis, leukocytosis, and elevated markers of inflammation, all resolved. Our observation suggests that Anakinra may be an attractive therapeutic approach for refractory multicentric CD.

PMID:
20501803
PMCID:
PMC3108331
DOI:
10.1158/1535-7163.MCT-10-0156
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for HighWire Icon for PubMed Central
Loading ...
Support Center